NewsRx

Search our medical news database

AIDS Therapies

Nucleoside Analogue Reverse Transcriptase Inhibitors Contribute to Fat Wasting

Published in AIDS Weekly, September 4th, 2000

Nucleoside analogue reverse transcriptase inhibitor (NRTI) therapy contributes to subcutaneous fat wasting in HIV patients, according to researchers in Australia.

"Progressive subcutaneous fat wasting, fat accumulation, dyslipidemia, and insulin resistance in HIV infected patients on antiretroviral therapy have been attributed to the long-term toxicity of HIV protease inhibitors (PI)," stated S.A. Mallal and colleagues, Royal Perth Hospital, Australia. "More recently, fat wasting has been observed in patients who have never taken a PI, implicating an independent effect of nucleoside analogue reverse transcriptase inhibitor (NRTI) therapy."

The...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook